{ "ok": true, "cik": "749647", "ticker": "IMNN", "name": "Imunon, Inc.", "filings": [ { "form": "8-K", "filed": "2026-09-29", "items": [ "1.01 Entry into a Material Definitive Agreement", "3.02 Unregistered Sales of Equity Securities", "5.03 Amendments to Articles or Bylaws; Change in Fiscal Year", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/749647/000149315226044792/0001493152-26-044792-index.htm" }, { "form": "8-K", "filed": "2026-08-11", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers" ], "url": "https://www.sec.gov/Archives/edgar/data/749647/000149315226037170/0001493152-26-037170-index.htm" }, { "form": "10-Q", "filed": "2026-08-11", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/749647/000149315226036991/0001493152-26-036991-index.htm" }, { "form": "8-K", "filed": "2026-08-11", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/749647/000149315226036985/0001493152-26-036985-index.htm" }, { "form": "8-K", "filed": "2026-06-30", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/749647/000149315226031292/0001493152-26-031292-index.htm" }, { "form": "8-K", "filed": "2026-06-16", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "5.07 Submission of Matters to a Vote of Security Holders", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/749647/000149315226028937/0001493152-26-028937-index.htm" } ], "events12m": 14, "healthWatch": { "window": "last 12 months", "since": "2025-09-30", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 6, "latest": { "filed": "2026-08-11", "url": "https://www.sec.gov/Archives/edgar/data/749647/000149315226037170/0001493152-26-037170-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000749647.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=749647" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up Imunon, Inc. ($IMNN). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-09-29. 14 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2022-12-31", "revenue": 500000, "revenueGrowth1y": 0, "revenueGrowthPerYear": 0, "yearsOfData": 5, "operatingMargin": -49.84313, "operatingMarginPrior": -42.01438, "netMargin": -71.796468, "operatingCashFlow": -23096895, "capitalSpending": 267800, "freeCashFlow": -23364695, "researchAndDevelopment": 11733666, "researchShareOfRevenue": 23.467332, "cash": 11492841, "longTermDebt": 5964280, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2018-12-31", "revenue": 500000 }, { "fiscalYearEnd": "2019-12-31", "revenue": 500000 }, { "fiscalYearEnd": "2020-12-31", "revenue": 500000 }, { "fiscalYearEnd": "2021-12-31", "revenue": 500000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 500000 } ], "totalEquity": 29327866, "totalAssets": 43975894, "equityRatio": 0.6669077836143593, "returnOnEquity": -1.22403157461235, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "latestAudited": { "fiscalYearEnd": "2025-12-31", "revenue": null, "operatingCashFlow": -13896624, "cash": 8781059, "totalEquity": 7061876, "totalAssets": 12288116, "equityRatio": 0.5746915149564018 }, "revenueYearIsOld": true, "earningsPerShare": -5.03, "sharesOutstanding": 7142970, "bookValuePerShare": 4.105836367785389, "revenuePerShare": 0.06999889401747453, "range80": { "low": 333262.0450207799, "high": 717714.074511798, "baseline": 500000, "n": 2483, "band": "b000", "bandLabel": "under $50M", "method": "v4.1", "credibility": 0.5714285714285714, "growthYears": 5, "ownVolatility": 0, "classVolatility": 0.3000583276631395, "volatility": 0.19643428563117127 }, "ifPaceHeld": { "low": 333262.0450207799, "high": 717714.074511798 } }, "edgarette": "🔖 Exposure: revenue $500K (FY2022), total debt $6.0M. Experience: revenue up 0.0% on the year, up 0.0% a year over 4 years; operating margin -4984.3%, down from -4201.4%. Soundness: equity 66.7% of assets, return on equity -122.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $333K and $718K next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $316K to $758K. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -4984.3% against a -3.8% median; growth 0.0% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Imunon (IMNN) grew revenue 0.0% in FY2022 to $1 million, operating margin -4984% against a -3.8% median for pharmaceutical preparations, equity 66.7% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Imunon, Inc. against its own record and its peers
Operating marginPeer median -3.8%-4984.3%Revenue, on the yearPeer median 13.7%0.0%Equity of assetsPeer median 40.3%66.7%Return on equityPeer median -1.1%-122.4%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 2, "hits": 2, "rate": 1, "method": "v4", "byYear": { "2021": [ 1, 1 ], "2022": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "caution": "Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2022, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Imunon (IMNN) grew revenue 0.0% in FY2022 to $1 million, operating margin -4984% against a -3.8% median for pharmaceutical preparations, equity 66.7% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2022-12-31", "revenue": 500000, "totalDebt": 5964280, "cash": 11492841 }, "experience": { "revenueGrowth1y": 0, "revenueGrowthPerYear": 0, "operatingMargin": -49.84313, "operatingMarginPrior": -42.01438, "netMargin": -71.796468, "freeCashFlow": -23364695 }, "soundness": { "equityRatio": 0.6669077836143593, "returnOnEquity": -1.22403157461235, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "healthWatch": { "window": "last 12 months", "since": "2025-09-30", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 6, "latest": { "filed": "2026-08-11", "url": "https://www.sec.gov/Archives/edgar/data/749647/000149315226037170/0001493152-26-037170-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": { "low": 333262.0450207799, "high": 717714.074511798, "baseline": 500000, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 2483, "sizeBand": "under $50M", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341, "coverageAllYears": 0.6904374799277399, "stressCoverageAllYears": 0.819004992974709, "outcomeYears": [ 2019, 2025 ] }, "credibility": { "weightOnOwnRecord": 0.571, "growthYears": 5, "ownVolatility": 0, "classVolatility": 0.3000583276631395, "pricedVolatility": 0.19643428563117127, "k": 3 }, "stress": { "low": 316183.20262871264, "high": 757866.3535218067, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a statistical range, not company guidance; no view on the share price", "track": { "backtest": { "tests": 2, "hits": 2, "rate": 1, "method": "v4", "byYear": { "2021": [ 1, 1 ], "2022": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": null, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2022, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000749647.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=749647" }, "speedCash": null, "harbor": { "signs": [ { "key": "cash", "text": "operating cash flow was negative (-$13.9M in FY2025)" }, { "key": "range", "text": "revenue is hard to predict: its 80% range is ±37%" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 2, "name": "Weathered boat", "plain": "two warning signs" }, "cashFlow": { "fiscalYearEnd": "2022-12-31", "operating": -23096895, "investing": 8280810, "financing": 6722654, "capitalSpending": 267800, "free": -23364695, "trend": [ { "fiscalYearEnd": "2018-12-31", "operating": -7041686, "free": -7180085 }, { "fiscalYearEnd": "2019-12-31", "operating": -20258982, "free": -20608140 }, { "fiscalYearEnd": "2020-12-31", "operating": -15618676, "free": -15637768 }, { "fiscalYearEnd": "2021-12-31", "operating": -16223603, "free": -16535216 }, { "fiscalYearEnd": "2022-12-31", "operating": -23096895, "free": -23364695 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2022-12-31", "cash": 11492841, "shortTerm": 21227991, "longTerm": null, "equityHoldings": null, "totalAssets": 43975894, "ladder": null, "currentRatio": 3.66, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": null, "harbor": { "signs": [ { "key": "cash", "text": "operating cash flow was negative (-$13.9M in FY2025)" }, { "key": "range", "text": "revenue is hard to predict: its 80% range is ±37%" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 2, "name": "Weathered boat", "plain": "two warning signs" }, "cashFlow": { "fiscalYearEnd": "2022-12-31", "operating": -23096895, "investing": 8280810, "financing": 6722654, "capitalSpending": 267800, "free": -23364695, "trend": [ { "fiscalYearEnd": "2018-12-31", "operating": -7041686, "free": -7180085 }, { "fiscalYearEnd": "2019-12-31", "operating": -20258982, "free": -20608140 }, { "fiscalYearEnd": "2020-12-31", "operating": -15618676, "free": -15637768 }, { "fiscalYearEnd": "2021-12-31", "operating": -16223603, "free": -16535216 }, { "fiscalYearEnd": "2022-12-31", "operating": -23096895, "free": -23364695 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2022-12-31", "cash": 11492841, "shortTerm": 21227991, "longTerm": null, "equityHoldings": null, "totalAssets": 43975894, "ladder": null, "currentRatio": 3.66, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }